Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (S…
Biotechnology
US, Cambridge [HQ]
Ratios
11 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||
| Gross Margin | - - | - - | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 99.95 | 90.04 | 91.27 | 90.19 | |
| Profit Margin | - - | - - | -462.89 | -261.04 | -691.30 | -531.53 | -494.20 | 39.54 | -357.67 | -273.24 | -203.30 | |
| Operating Margin | - - | - - | -465.10 | -265.04 | -697.64 | -554.86 | -551.16 | 38.07 | -360.10 | -269.19 | -194.99 | |
|
EPS Growth
|
- - | -92.50 | 6.17 | 8.65 | -48.49 | -37.50 | -27.46 | 183.84 | -291.15 | 15.08 | 10.48 | |
| EPS USD | -160.00 | -308.00 | -289.00 | -264.00 | -392.00 | -539.00 | -687.00 | 576.00 | -1,101.00 | -935.00 | -837.00 | |
| Return on Assets (ROA) | -505.73 | -80.69 | -29.50 | -25.64 | -20.69 | -43.81 | -46.45 | 18.27 | -51.44 | -41.30 | -48.32 | |
| Return on Equity (ROE) | 1,397.86 | -113.71 | -36.65 | -34.02 | -23.74 | -56.48 | -70.79 | 21.35 | -66.35 | -108.32 | -388.17 | |
| Return on Invested Capital (ROIC) | -1,546.13 | -90.36 | -34.48 | -33.26 | -23.54 | -59.25 | -61.85 | 19.31 | -60.20 | -73.23 | -59.20 | |
| Solvency | ||||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 69.24 | 18.11 | 4.36 | 2.30 | 2.73 | 3.02 | 13.56 | 5.21 | 8.90 | 17.96 | 65.99 | |
| Debt/Equity | -191.38 | 25.52 | 5.41 | 3.05 | 3.14 | 3.90 | 20.66 | 6.10 | 11.48 | 47.11 | 530.11 | |
| Debt/EBITDA | -4.32 | 97.42 | 304.88 | 367.71 | 444.24 | 22.59 | 4.98 | -192.75 | 15.35 | -22.84 | -148.09 | |
|
Debt/Capitalization
|
209.44 | 20.33 | 5.13 | 2.96 | 3.04 | 3.75 | 17.12 | 5.74 | 10.30 | 32.02 | 84.13 | |
| Long-Term Debt/Capitalization | 327.01 | 17.16 | 2.67 | 1.56 | 2.55 | 3.37 | 16.10 | 5.26 | 9.62 | 29.47 | 82.39 | |
| Interest Debt per Share USD | 0.23 | 0.73 | 0.47 | 0.25 | 0.52 | 0.37 | 2.29 | 1.64 | 1.90 | 4.35 | 12.29 | |
| Debt Growth | - - | 215.82 | -56.34 | -14.64 | 384.60 | -10.50 | 556.42 | -6.61 | 24.33 | 117.62 | 219.29 | |
| Liquidity | ||||||||||||
| Current Ratio | 77.64 | 713.69 | 914.25 | 773.10 | 1,598.29 | 828.52 | 485.33 | 709.29 | 369.93 | 571.21 | 376.13 | |
| Quick Ratio | 63.02 | 698.40 | 891.21 | 1,521.76 | 2,206.59 | 818.94 | 476.10 | 685.89 | 343.30 | 535.89 | 350.74 | |
| Cash Ratio | 63.02 | 698.40 | 872.89 | 940.72 | 1,569.96 | 112.83 | 107.00 | 523.41 | 140.18 | 65.33 | 33.17 | |
| Operating Cash Flow Ratio | -600 | -500 | -100 | - - | -200 | -200 | -200 | 200 | -100 | -200 | -200 | |
| Turnover | ||||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | - - | 4.95 | 82.20 | 59.98 | 115.26 | |
| Receivables Turnover | - - | - - | 333.92 | 776.41 | - - | - - | 284.09 | 3,136.18 | 486.31 | 552.37 | 577.56 | |
| Payables Turnover | - - | - - | - - | - - | - - | - - | - - | 9.73 | 215.22 | 652.73 | 519.34 | |
|
Asset Turnover
|
- - | - - | 6.37 | 9.82 | 2.99 | 8.24 | 9.40 | 46.19 | 14.38 | 15.11 | 23.77 | |
| Fixed Turnover | - - | - - | 171.15 | 448.80 | 87.94 | 150.27 | 59.86 | 780.71 | 149.00 | 177.12 | 215.63 | |
| Coverage | ||||||||||||
| Interest Coverage | -15,053.62 | -8,792.94 | -7,617.96 | -15,694.67 | -67,636.20 | -338,394.52 | -2,669.57 | - - | - - | -3,275.80 | -942.31 | |
| Asset Coverage | - - | 400 | 4,100 | 7,600 | 4,100 | 3,200 | 600 | 1,700 | 900 | 400 | 100 | |
| Cash Flow Coverage (CFGR) | -664.51 | -391.51 | -406.52 | -377.18 | -612.71 | -1,071.64 | -289.75 | 431.94 | -268.07 | -207.17 | -63.09 | |
| EBITDA Coverage | -14,600 | -8,600 | -7,400 | -15,300 | -66,900 | -324,000 | -2,600 | - - | - - | -3,200 | -900 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | 100 | - - | - - | - - | |
| Market Prospects | ||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -8.47 | -16.32 | -10.99 | -9.40 | -5.20 | -10.01 | -8.58 | 5.13 | -10.28 | -21.34 | -9.08 | |
|
Price/Earnings (P/E)
|
-1,180.55 | -612.82 | -910.24 | -1,063.72 | -1,924.10 | -999.34 | -1,165.67 | 1,948.50 | -973.14 | -468.67 | -1,101.78 | |
| Price/Earnings Growth (PEG) | - - | -6.63 | 147.56 | 122.97 | -39.68 | -26.65 | -42.45 | -10.60 | 3.34 | 31.08 | 105.12 | |
|
Price/Book (P/B)
|
-16,502.42 | 696.82 | 333.61 | 361.91 | 456.75 | 564.40 | 825.13 | 416.03 | 645.68 | 507.68 | 4,276.79 | |
| Price/Tangible Book (P/TB) | -16,502.42 | 696.82 | 333.61 | 361.91 | 456.75 | 564.40 | 825.13 | 416.03 | 645.68 | 507.68 | 4,276.79 | |
| Price/Sales (P/S) | - - | - - | 4,213.39 | 2,776.69 | 13,301.43 | 5,311.81 | 5,760.74 | 770.53 | 3,480.60 | 1,280.62 | 2,239.90 | |
|
Price/Cash Flow (P/CF)
|
-1,297.64 | -697.39 | -1,516.37 | -3,145.85 | -2,377.65 | -1,351.28 | -1,378.19 | 1,580.22 | -2,098.71 | -520.21 | -1,278.68 | |
| Price/Free CF (P/FCF) | -1,280.35 | -683.87 | -1,313.84 | -2,870.22 | -2,105.21 | -1,260.01 | -1,312.06 | 1,593.22 | -1,119.47 | -511.14 | -1,233.33 | |
| Price/Operating CF (P/OCF) | -1,297.64 | -697.39 | -1,516.37 | -3,145.85 | -2,377.65 | -1,351.28 | -1,378.19 | 1,580.22 | -2,098.71 | -520.21 | -1,278.68 |